Skip to main content

Table 1 Maternal and neonatal characteristics

From: Risk adapted transmission prophylaxis to prevent vertical HIV–1 transmission: Effectiveness and safety of an abbreviated regimen of postnatal oral Zidovudine

  Total ninfected
  114 2
Gestational age at delivery   
 < 33. +  0 weeks 1 0
 33. +  0-36. + 6 weeks 51 1
 ≥ 37. +  0 weeks 62 1
Maternal HIV-1 RNA at delivery   
 < 50 55 0
 50–2999 44 1
 3000 – 10000 7 0
 > 10000 7 1
 missing viral load at birth 1 0
Maternal CD4 cell count at delivery (cells/μl) ( n = 104, missing data n = 10)   
 < 200 11 1
 200 – 349 26 1
 ≥ 350 67 0
Gender of neonate   
 female 66 2
 male 48 0
Mode of delivery   
 elective cesarean 77 2
 emergency cesarean 33 0
 vaginal delivery 4 0
Initiation of antenatal ART (weeks) (n = 112, missing data n = 2)   
 none 3 0
 non-stop from onset 24 1
 ≤ 20 15 0
 21 – 28 17 0
 > 28 53 1
Last antenatal art (n = 113, missing data n = 1)   
 HAART 95 2
 dual-drug therapy 12 0
 Monotherapy 3 0
 none 3 0
Intrapartum prophylaxis   
 Yes 113 2
 No 1 0
Duration of postnatal child prophylaxis (weeks)   
 2 74 2
 4 8 0
 6 32 0
Postnatal child prophylaxis   
 dual or HAART 12 0
 Monotherapy 102 2
At-risk-group/risk of infection   
 low risk 78 1
 high risk 26 0
 very high risk 10 1
Complete Prophylaxis   
 Yes 105 1
 No 9 1